Navigation Links
Latest Drug for AMD, Beyond The Reach Of Common Man

Lucentis is the new drug which is claimed to be very effective in treating age-related macular degeneration (AMD) It is not been approved by the FDA //but is thought to replace another proven and cost effective drug. Lucentis is manufactured by Genentech and is already called the wonder drug. AMD is a chronic eye disease affecting 1.7 million Americans and a leading cause of blindness in the country.

Dr. Philip Rosenfeld, a macular-degeneration specialist in Miami said that the drug can be replaced by Avastin which has a very similar molecular structure. About 10,000 people were administered Avastin which has given very good results. Lucentis can't repair the irreversible retina damage but prevents the blood-vessel leakage in the back of the eye that causes damage. The patients suffer from distorted, wavy vision, and eventually a gap in the center of their vision. In the trails session itself Lucentis was found to have improved the patient’s eyesight by at least three lines on a vision chart.

The only disadvantage is that Lucentis will cost more than 100 times as much as the temporary fix. A dose of Avastin for the eye costs about $13 whereas Lucentis cost up to $3000 for a single dose. Doctors too will most likely turn to the more expensive drug. The problem is that Avastin has not been subjected to rigorous testing for AMD, and it would take Genentech years and huge amount of money to do those tests with Avastin. Megan Pace, spokeswoman for the company said that the cost factor would be taken care of by the company and hence patients need not worry about it.


'"/>




Page: 1

Related medicine news :

1. Latest device for identifying Melanomas
2. Latest discovery on Autism
3. Latest device for cardiac revival under test
4. Latest technique for asthma treatment
5. Latest drug shows promise in multiple myeloma
6. Latest Findings On The Deadly Disease - SARS
7. Latest Tumor Classification More Informative
8. The Latest Preventative Treatment Option for Prostate Cancer
9. Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly
10. A Latest Study Links Fish To Stroke
11. Enhanced Gene Therapy Outcomes Following Latest Revolution And Refinement
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today ... for and donate to Give To Cure’s campaign that is crowdfunding clinical trials to ... make and share payments through a smart device. In 2015 alone, Venmo processed $7.5 ...
(Date:2/5/2016)... ... , ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental ... individuals in need. The event is scheduled to take place on February 27, 2016 ... provide dental care to community members in need. Each patient will be given the ...
(Date:2/5/2016)... , ... February 05, 2016 , ... In sleep, when ... as a dream. A hallmark feature of patients with eating disorders is significant self-criticism, ... eating disorder behaviors and obsessions are regarded as maladaptive means for coping with this ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
(Date:2/5/2016)... ... 05, 2016 , ... When one is tired of trying to cram belongings into spare space ... to rent a storage unit, but before hastily spending money on a unit, take these ... more space. But what one is often not told when utilizing these services are some ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Syneron Medical Ltd. (NASDAQ: ELOS ... today that William Griffing , Chief Executive ... to participate in the Leerink Partners 5 th ... 2016 in New York City ... meet with the Mr. Griffing and will include ...
(Date:2/5/2016)... , Feb. 5, 2016  Patients in Alabama ... focused ultrasound (HIFU) therapy no longer have to travel out ... its partnership with Urology Centers of Alabama to ... FDA-cleared procedure for qualifying patients. Alabama ... in the treatment of prostate cancer using many different modalities. ...
(Date:2/5/2016)... -- Aethlon Medical, Inc. (Nasdaq: AEMD ), today announced ... presenting at Source Capital Group,s 2016 Disruptive Growth & Healthcare ... 2:15 p.m. ET on Wednesday, February 10, 2016.  Mr. Joyce ... at 3:15 p.m. ET. http://www.aethlonmedical.com .  The webcast ... conclusion of the live event. The panel discussion will not ...
Breaking Medicine Technology: